TY - JOUR
T1 - Can sodium-glucose cotransporter 2 inhibitors ‘spin the thread of life’?
AU - Maltese, Giuseppe
AU - Koufakis, Theocharis
AU - Kotsa, Kalliopi
AU - Karalliedde, Janaka
N1 - Publisher Copyright:
© 2022 Elsevier Ltd
PY - 2023/1
Y1 - 2023/1
N2 - Sodium-glucose cotransporter 2 inhibitors (SGLT2i) were first used as antidiabetic agents that lower the blood glucose levels by promoting glycosuria. In recent years, randomised clinical trials have demonstrated that SGLT2i reduce cardiovascular-renal events and all-cause mortality in people with and without diabetes. The cardio-renal benefits observed are independent of glucose lowering effect and multiple mechanisms have been proposed for these results. SGLT2i can exert anti-ageing effects on the vasculature and other body organs through several signalling pathways including the activation of the nuclear factor erythroid-2-related factor 2 and the induction of antioxidant enzymes. We speculate that the pro-longevity effects of the SGLT2i are mediated by soluble Klotho, an anti-ageing kidney-derived hormone and an emerging therapeutic target for cardio-renal diseases.
AB - Sodium-glucose cotransporter 2 inhibitors (SGLT2i) were first used as antidiabetic agents that lower the blood glucose levels by promoting glycosuria. In recent years, randomised clinical trials have demonstrated that SGLT2i reduce cardiovascular-renal events and all-cause mortality in people with and without diabetes. The cardio-renal benefits observed are independent of glucose lowering effect and multiple mechanisms have been proposed for these results. SGLT2i can exert anti-ageing effects on the vasculature and other body organs through several signalling pathways including the activation of the nuclear factor erythroid-2-related factor 2 and the induction of antioxidant enzymes. We speculate that the pro-longevity effects of the SGLT2i are mediated by soluble Klotho, an anti-ageing kidney-derived hormone and an emerging therapeutic target for cardio-renal diseases.
UR - http://www.scopus.com/inward/record.url?scp=85144596815&partnerID=8YFLogxK
U2 - 10.1016/j.tem.2022.10.002
DO - 10.1016/j.tem.2022.10.002
M3 - Short survey
SN - 1043-2760
VL - 34
SP - 1
EP - 4
JO - TRENDS IN ENDOCRINOLOGY AND METABOLISM
JF - TRENDS IN ENDOCRINOLOGY AND METABOLISM
IS - 1
ER -